Man Group plc Acquires Shares of 310,617 Xenon Pharmaceuticals Inc. $XENE

Man Group plc acquired a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 310,617 shares of the biopharmaceutical company’s stock, valued at approximately $18,749,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of Xenon Pharmaceuticals in the 2nd quarter valued at about $454,057,000. Jupiter Topco LLC purchased a new position in Xenon Pharmaceuticals during the 2nd quarter worth approximately $252,673,000. Holocene Advisors LP acquired a new position in Xenon Pharmaceuticals during the second quarter worth approximately $56,637,000. Wellington Management Group LLP increased its position in Xenon Pharmaceuticals by 66.0% during the third quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock worth $144,936,000 after buying an additional 1,435,096 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its stake in Xenon Pharmaceuticals by 1,968.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 862,300 shares of the biopharmaceutical company’s stock valued at $38,650,000 after buying an additional 820,608 shares during the last quarter. Institutional investors and hedge funds own 95.45% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on XENE. HC Wainwright reiterated a “buy” rating and set a $74.00 target price on shares of Xenon Pharmaceuticals in a research note on Monday, August 10th. JPMorgan Chase & Co. boosted their price target on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a research report on Wednesday, May 27th. Wall Street Zen upgraded Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Wells Fargo & Company reissued an “overweight” rating and issued a $69.00 target price on shares of Xenon Pharmaceuticals in a report on Sunday, May 10th. Finally, Royal Bank Of Canada dropped their target price on Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating on the stock in a report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $77.13.

Xenon Pharmaceuticals Stock Performance

XENE stock opened at $61.93 on Friday. The stock has a market capitalization of $5.99 billion, a PE ratio of -13.07 and a beta of 0.62. The company has a fifty day moving average of $63.04 and a 200-day moving average of $56.36. Xenon Pharmaceuticals Inc. has a one year low of $35.60 and a one year high of $72.66.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.05. During the same quarter last year, the business earned ($1.07) EPS. Equities analysts forecast that Xenon Pharmaceuticals Inc. will post -4.73 earnings per share for the current fiscal year.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Steven Gannon sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $64.06, for a total transaction of $640,600.00. Following the transaction, the director owned 1,870 shares in the company, valued at approximately $119,792.20. The trade was a 84.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Gary Patou sold 1,322 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $70,251.08. Following the transaction, the director owned 24,896 shares in the company, valued at $1,322,973.44. The trade was a 5.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 12,512 shares of company stock valued at $774,088. 2.91% of the stock is owned by corporate insiders.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.